Portage Biotech, Inc. (PRTG)
|Net Income (ttm)||n/a|
|Trading Day||April 21|
|Day's Range||27.03 - 28.86|
|52-Week Range||26.50 - 37.50|
Common shares will be consolidated on the Nasdaq exchange where shareholders can continue trading under the symbol "PRTG"Westport, Connecticut--(Newsfile Corp. - April 16, 2021) - Portage Biotech Inc.,...
Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive ...
- Novel platform allows co-targeting of iNKT cells and tumor antigens in a single product- Trial marks the first milestone in a comprehensive clinical development plan to evaluate iNKT agonists to impro...
Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensi...
- The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment - Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 months...
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, ... [Read more...]
|Stock Exchange |
|Ticker Symbol |